Coronavirus

Although the advisory committee’s recommendation is not binding, the FDA will take their recommendation into consideration when making a final decision on authorization of the 50-µg booster dose.

Study indicates COVID-19 vaccination is important for individual protection and for reducing transmission within families.

The agency has a 2-day meeting scheduled for this week for an independent advisory panel to discuss the available data.

New study results show that previously infected patients had molecular markers that suggested that immune cells could last longer and migrate more effectively to the respiratory tract.

A phase 3 trial met the primary endpoint, and the long-acting antibody combination reduced symptoms or death by 67% for patients compared with those who took a placebo.

The study aimed to examine the impact of masking and social distancing practices used to control the spread of COVID-19.

There is a real opportunity for technology to alleviate some of the administrative burdens pharmacists face so that they have more time to focus on patient care.

Samples for the test are isolated from nasopharyngeal swabs, anterior nasal swabs, and mid-turbinate swabs.

Anna Legreid-Dopp, PharmD, Senior Director of Clinical Guidelines and Quality Improvement at the American Society of Health-System Pharmacists discusses Pfizer’s request to approve their COVID-19 vaccine for children 5 to 11.

In an interview with Pharmacy Times®, Rita Carreón, VP of health at UnidosUS, discusses the impact of the COVID-19 educational mobile tour, launched by AARP and UnidosUS.

Michael Frank, CEO of Revive Therapeutics, discussed the results of a phase 3 trial investigating bucillamine as an oral at-home pill for the treatment of COVID-19 symptoms.

Those who are younger than aged 40 years tend to regain these senses at higher rates than those who are older.

A town hall meeting with representatives from the agencies emphasized the effectiveness and likelihood of getting a third dose of the vaccine.

Vaccine efficacy was 93% against the Delta variant at 1 month after the 2-dose vaccine regimen, although it fell to 53% after 4 months.

The phase 3 ENSEMBLE 2 study found that a booster of Johnson & Johnson’s single-shot vaccine administered 56 days after the primary dose provided 94% protection against symptomatic COVID-19.

AZD7442 (AstraZeneca), a long-acting antibody combination, reduced the risk of developing symptomatic COVID-19 by 77% compared to placebo.

Labcorp’s collection kit can simultaneously detect the coronavirus and influenza A/B in individuals aged 2 years and older, and results can be determined in 1 to 2 days.

Seronegative patients with COVID-19 who required low-flow or no supplemental oxygen receiving Ronapreve had significant reductions in viral load within 7 days of treatment.

With the Delta variant, there was an increase in coronavirus-related hospitalizations by more than one-third among these individuals.

Molnupiravir reduced the risk of hospitalization or death by approximately 50% among patients with COVID-19 who received the drug.

The main factors behind the vaccine hesitancy are the potential adverse effects post-vaccination and effect on their autoimmune conditions, as well as lack of trial data, an analysis shows.

Among 38 patients with B-cell derived malignancies who were seronegative after 2 COVID-19 vaccine doses, 55% had detectable antibodies after the third dose whereas 45% remained seronegative.

Individuals who used intranasal corticosteroids prior to being infected were about 22% less likely to be hospitalized from severe COVID-19 than those who did not.

T2D is associated with a higher mortality risk linked to the coronavirus than individuals with T1D.

The results were compared to those in the previous Pfizer-BioNTech study in people between 16 and 25 years of age who were immunized with 30 μg doses.

Co-administration of COVID-19 vaccines and flu vaccines is also available.

The COVID-19 booster doses are to be administered at least 6 months after completion of the primary 2-dose series and are the same formulation and dosage strength as the original doses.

Remdesivir demonstrated a statistically significant 87% reduction in risk for the composite primary endpoint of COVID-19-related hospitalization or all-cause death by day 28.

It demonstrated 93.2% efficacy 14 days afterward and greater than 90% for 4 or more months.

In part 2 of their discussion on COVID-19 vaccine mandates, experts Ned Milenkovich, PharmD, and Ron Lanton III, Esq., discussed how provider status could impact potential legal issues around COVID-19 vaccine mandates.